CHINA LEX PHARMA LAW NEWSLETTER
Vol. 3 , No.1 - January 14, 2002
TOPICS THIS ISSUE:
- 298 Staff Punished In Hospital Crackdowns
- Despite Third Quarter Index Decreases, Expectations Remain High
- Top Ten Medical News Stories In China In 2001
- Intranet For Hospitals To Be Created In Shanghai
- Eight Private Hospitals Open in Beijing
- List of China GMP Facilities (Continued)
298 Staff Punished In Hospital Crackdowns
In the eastern Chinese province of Shandong, almost 300 hospital workers have been disciplined for receiving commissions or excessively charging patients.
It has been reported that in five of the 298 cases, the violations were considered to be so severe that the workers have been turned over to the judicial authorities for further prosecution.
The large number of disciplinary measures are the result of a half-year investigation into the medical practice throughout Shandong.
(Source: Agence France Presse)
Despite Third Quarter Index Decreases, Expectations Remain High
The State Economic and Trade Commission and the National Bureau of Statistics predicts that despite the sharp decline in the third quarter, the pharmaceutical industry will achieve its yearly objectives.
In the July-September quarter, the industry's index fell 0.11. However, it is believed that in the last quarter, it will rise 0.20 and thus meet the goals set at the beginning of the year.
In the first three quarters of 2001, the industrial output value amounted to RMB 198.5 billion, an increase of 17.7 percent from the first three quarters of 2000. Sales revenue increased 16.2 percent relative to the same period of time of the previous year to RMB 148.1 billion and profits in the industrial enterprises in the industry reached RMB 11.47 billion, up 22.7 percent from the previous year. The net value of accounts receivable was up 11.1 percent to RMB 52.18 billion.
Import and export of pharmaceutical products for the first 8 months totaled US$ 4.99 billion, an increase of 21 percent from 2000. Exports increased 12.6 percent to reach US$ 2.78 billion and imports increased 32.8 percent to reach US$ 2.21 billion.
In the third quarter of 2001, indexes fell heavily relative to the second quarter, with the production capacity index falling 0.18 to 0.04, the utilization of funds index falling 0.17 to 0.16, the sale index falling 0.27 to 0.24 and the profit index falling 0.27 to 0.20.
However, despite the dramatic falls in the industry indexes of the third quarter, the industry outlook for the final quarter remained optimistic. It is thought that the comprehensive performance index will increase 0.11 to reach 0.20.
(Source: Asia Pulse)
Profitable China GMP Facility for Sale
Send email to mail@chinalaw.cc for further information. |
Top Ten Medical News Stories In China In 2001
A project commemorating the top ten medical news stories for the year 2001 was jointly prepared by the Ministry of Health, the Ministry of Science and Technology, the State Drug Administration, the State Administration of Traditional Chinese Medicine, the China Association for Science and Technology, Chinese Medical Association, and China Health News.
Following are short summaries of the top ten medical news stories in China:
1. The smooth progress of the human genome program;
2. China's breakthrough in the areas of biology techniques and medical sciences, which produced over US$ 1 billion in profit;
3. Progress made by the No.3 Medical College of the Chinese People's Liberation Army in the research and surgical treatment of liver and gall bladder diseases;
4. The regulations for human aided reproduction technology and sperm use;
5. The cooperation project between the Chinese Academy of Sciences and the Chinese Academy of Medical Sciences on viral medicines, which created independent intellectual property;
6. The discovery by Shu Siyun, a professor with the No.1 Medical College of the Chinese People's Liberation Army, of a new region in the cerebrum relating to studying and memory;
7. The publication of an article by the medical staff at the No. 301 Hospital of the Chinese People's Liberation Army in the medical magazine "Lancet". The article reports for the first time that epidermis cells may cause counter differentiation phenomenon;
8. The launching by the Ministry of Health of a priority medical plan for western China;
9. China's research into new drugs; and
10. China's discovery of new diseases.
(Source: Xinhua News Agency)
Intranet For Hospitals To Be Created In Shanghai
The Shanghai public health department has announced that an intranet for hospitals will be soon be established. The network will provide information on medical research programs and progress in the city's hospitals as well as access to medical journals and reference books.
The network, which has already been in trial operation in five hospitals, will include a number of various databases in the medical field and an e-mail system for medical experts to exchange ideas.
(Source: Xinhua News Agency)
Eight Private Hospitals Open in Beijing
The Beijing medical administration department has permitted the establishment of eight commercial hospitals in the capital city of China. The hospitals, able to offer a level of quality of medical services previously not available, officially opened on December 30.
According to regulations made by the Beijing Municipal Public Health Bureau, the hospitals have the freedom of being able to charge higher fees and decide how to best serve their patients.
Patients at the eight commercial hospitals will have the responsibility of paying their medical bills themselves, regardless of whether or not they have medical insurance for the government hospitals. Compared to the government-run and subsidized hospitals, where the prices are standardized by the government, the new commercial hospitals will offer more complete and patient-orientated services, and will thus charge much higher prices.
Jin Dapeng, deputy director of the BMPHB, said that despite the new addition of the commercial hospitals into the medical service industry, public hospitals will remain as the principal care-giver for the Beijing masses.
(Source: BBC)
China Pharma Distribution Company for Sale
Send email to mail@chinalaw.cc for further information. |
List of China GMP Facilities (Continued)
Name of Enterprise | Certified Scope |
551. Guangzhou Yuehua Pharmaceutical Co., Ltd. | Tablet, Capsule |
552. Gansu Dingxifuzheng Pharma Co., Ltd. | High dose injection |
553. Guangdong Hongyuan Group Pharma Co., Ltd. | High dose injection, Freeze-dried powder-injection |
554. Hangzhou Tongda Pharma Co., Ltd. | Wet dressing agent |
555. Guangdong Liguo Pharma Co., Ltd. | Bulk (Cephalosporin) |
556. Shenzhen Pharma Factory | Tablet, capsule, granule |
557. Kaifeng Yugang Pharma Co., Ltd. | Bulk (Cephalosporin), powder-injection |
558. Chengdu Tiantaishan Pharma Co., Ltd. | Low dose injection |
559. Xiamen Jianfa Pharma Co., Ltd. | Powder-injection |
560. Livzon Group Libao Biochemical &Pharma Co., Ltd. | Freeze-dried powder-injection, Low dose injection |
561. Hualan Bio-engineering Co., Ltd. | Blood Product |
562. Shenzhen Pharmaceutical Factory | Tablet, capsule, granule |
563. Shanghai Union Saier Bio-engineering Co., Ltd. | Recombinant human hormone growth |
564. Xuzhou 5th Pharma Factory | High dose injection |
565. Dongtai Kangyi Pharma Co., Ltd. | High dose injection |
566. Guangdong qingfa Pharma Co., Ltd. | Ointment, suppository |
567. Changchun Jinsai Pharma Co., Ltd. | Recombinant human growth hormone |
568. Fujian Huitian Bio-pharma Co., Ltd. | Powder-injection (penicillin) |
569. Shandong Lunan Pharma Factory | Tablet, capsule, high dose injection,granule, low dose injection |
570. Shandong Lunan Pharma Factory | Tablet (penicillin) |
571. Qingdao Haier Pharma Co., Ltd. | Granule, capsule |
572. Qingdao Haier Pharma Co., Ltd. | Tablet, capsule |
573. Tianjin Tianyao Pharma Co., Ltd. by Shares | Bulk |
574. Hainan Union Pharma Co., Ltd. | Tablet, Capsule, low dose injection,freeze-dried powder-injection |
575. Guizhou Yibai Pharma Co., Ltd. | Capsule, low dose injection |
576. Guangzhou Yangjiang Pharma Factory | Freeze-dried powder-injection |
577. Guizhou Sanli Pharma Co., Ltd. | Capsule, spray |
578. Guangzhou Tianxin Pharma Co., Ltd. by Shares | Powder-injection |
579. Guangzhou Qiaoguang Pharma Factory | High dose injection |
580. Harbin Pharma Group Pharmaceutical Factory | Bulk, powder-injection (penicillin, Cephalosporin) |
581. Jiangsu Yangzijiang Pharma Group Company | Tablet, capsule |
582. Changzhou Jinyuan Pharma Co., Ltd. | Freeze-dried powder-injection |
583. Hubei Boren Pharma Co., Ltd. | High dose injection |
584. Beijing Shuanghe Pharma Co., Ltd. by Shares | High dose injection, low dose, freeze-dried powder-injection |
585. Beijing Tongrentang Pharma Factory | Pill |
586. Beijing Ruide Hetong Pharma Co., Ltd. | Freeze-dried powder-injection |
587. Guangzhou Baite Medical Product Co., Ltd. | High dose injection |
588. Hangzhou Merck Pharma Co., Ltd. | Tablet |
589. Tainjin 6th Chinese Traditional Medical Factory | Pill |
590. Guangdong Kangmei Pharma Co., Ltd. by Shares | Tablet, capsule |
591. Beijing Fresenius Kabi Pharma Co., Ltd. | High dose injection |
592. Shenzhe Wanle Pharma Co., Ltd. | Freeze-dried powder-injection |
593. Tainan Pharma (Xiamen) Co., Ltd. | Tablet, capsule |
594. Tainan Pharma (Xiamen) Co., Ltd. | Granule |
595. Zhuhai Unite Pharma Co., Ltd (Zhongshan Branch) | Tablet, oral liquid, capsule |
596. Zhuhai Unite Pharma Co., Ltd (Zhongshan Branch) | Dry syrup (cephalosporin) |
597. Zhuhai Unite Pharma Co., Ltd (Zhongshan Branch) | Powder-injection, bulk |
598. Harbin Pharma Co., Ltd. by Shares TCM 2nd Branch | Freeze-dried powder-injection |
599. Anhui Green Cross Bio-products Co., Ltd. | Blood product |
600. Guangdong Otsuke Pharma Co., Ltd. | High dose injection |
Lehman Lee & Xu
China Lawyers, Notaries, Patent, Copyright and Trademark Agents
http://www.chinalaw.cc/
Beijing Office | Shanghai Office |
6th floor, Dongwai Diplomatic Office Building
23 Dongzhimenwai Dajie
Beijing 100600 China
Tel.: (86)(10) 8532-1919
Fax: (86)(10) 8532-1999
Email: mail@chinalaw.cc | Suite 5107, Plaza 66
No. 1266, West Nanjing Road
Shanghai 200040 China | | Tel: | (86)(21) 6375-8240
(86)(21) 6288-1635/6 | Fax: | (86)(21) 6375-8705
(86)(21) 6288-1635/6 | | | |
To unsubscribe from this newsletter send an email to unsubscribe_lp@chinalaw.cc Please include the email address to which the newsletter is being sent (not a forwarded address) in the body of the email.
The China Lex Pharma Law Newsletter is intended to be used for news purposes only. It should not be taken as comprehensive legal advice, and Lehman, Lee & Xu will not be held responsible for any such reliance on its contents.
